We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Zentalis Pharmaceuticals Inc (ZNTL) USD0.001

Sell:$12.68 Buy:$12.71 Change: $0.16 (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$12.68
Buy:$12.71
Change: $0.16 (1.24%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$12.68
Buy:$12.71
Change: $0.16 (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zentalis Pharmaceuticals Inc is a United States-based company. The Company develops small molecule therapeutics with differentiated product profiles for a broad range of cancers. It is focused on pipeline of oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a B-cell lymphoma 2 (BCL-2) inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies.

Contact details

Address:
1359 Broadway, Suite 801
NEW YORK
10018
United States
Telephone:
+1 (212) 4333791
Website:
https://www.zentalis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZNTL
ISIN:
US98943L1070
Market cap:
$901.90 million
Shares in issue:
70.96 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Cam Gallagher
    President, Executive Director
  • Kimberly Blackwell
    Chief Executive Officer, Director
  • Melissa Epperly
    Chief Financial Officer, Treasurer
  • Iris Roth
    Chief Operating Officer
  • Mark Lackner,
    Chief Scientific Officer
  • Andrea Paul
    General Counsel, Corporate Secretary
  • Kimberly Freeman
    Chief Strategy Officer
  • Diana Hausman
    Chief Medical Officer
  • Kyle Rasbach
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.